Enveda secures $55 million in Series B extension to integrate ancient remedies with AI for drug discovery.

Jun 14, 2024•over 1 year ago

Amount Raised

$55 Million

Round Type

series b

Boulder

Investors

Jazz Venture PartnersLevel VenturesFpvTrue VenturesKinnevikLingotto Investment FundPremji InvestThe Nature ConservancyMicrosoft

Description

Enveda announced a $55 million Series B extension from new investors to integrate ancient remedies with AI to discover new drugs. The latest funding round brings Enveda’s total capital to $230 million and involves contributions from both new and existing investors.

Company Information

Company

Enveda Biosciences

Location

1880 S Flatiron Ct. Ste. K

Boulder, Colorado, United States

About

Enveda Biosciences is a biotechnology company building the first high-resolution chemical map of the natural world to tackle the toughest problems in drug discovery. Enveda’s platform is the world’s most advanced drug discovery search engine for dark chemical space, building on years of cutting-edge advancements at the intersection of metabolomics and machine learning. Complementing its breakthrough technology, Enveda’s team includes seasoned drug hunters with decades of experience in the pharmaceutical industry working alongside world-leading data scientists. For more information on Enveda, visit envedabio.com.

Related People

7 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends